EP1438005A1 - Utilisation d'une ou de plusieurs substances selectionnees dans le groupe des pyrimidines ou des purines dans des preparations cosmetiques de coloration capillaire - Google Patents

Utilisation d'une ou de plusieurs substances selectionnees dans le groupe des pyrimidines ou des purines dans des preparations cosmetiques de coloration capillaire

Info

Publication number
EP1438005A1
EP1438005A1 EP02785162A EP02785162A EP1438005A1 EP 1438005 A1 EP1438005 A1 EP 1438005A1 EP 02785162 A EP02785162 A EP 02785162A EP 02785162 A EP02785162 A EP 02785162A EP 1438005 A1 EP1438005 A1 EP 1438005A1
Authority
EP
European Patent Office
Prior art keywords
hair
group
purines
acid
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02785162A
Other languages
German (de)
English (en)
Inventor
Werner Berens
Rainer Wolber
Christoph Smuda
Franz STÄB
Thomas Blatt
Kyra Giesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1438005A1 publication Critical patent/EP1438005A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair

Definitions

  • the invention relates to a new use and a new method for dyeing hair, for example gray hair, in particular living human hair, with one or more substances selected from the group of pyrimidines and purines, and preparations which are used in the Execution of the method can be used.
  • the structure of all these hairs is roughly similar: the central hair mark (made of epithelial cells with eosinophilic granules of the trichohyalin granule), surrounded by the hair cortex (from horny cells; contains pigments) and the epidermis (cuticle pili; coreless epidermal layer) ) and layers of the epithelial and connective tissue hair sheath.
  • the hair is divided into the hair shaft protruding from the skin and the oblique hair root reaching into the subcutis, the layers of which correspond approximately to those of the epidermis.
  • the thickened lower end of the root, the hair bulb sits on a vascular connective tissue cone that protrudes into it, the hair papilla (both as a hair floor).
  • Melanin is responsible for the personal hair color. Melanin is formed in the melanocytes, cells that occur in the hair bulb in association with the keratinocytes of the hair market. As characteristic cell organelles, melanocytes contain melanosomes in which the melanin is formed. This is transferred via the long dendrites of the melanocytes into the keratinocytes of the precortical matrix and creates the more or less pronounced blonde to brown-black hair color.
  • DHICA and DHI melanin are produced via the common intermediate stages dopaquinone and dopachrome. The latter is implemented, partly with the participation of further enzymes, either in indole-5,6-quinone carboxylic acid or in indole-5,6-quinone, from which the two eumelanins mentioned arise.
  • the formation of phaeomelanin takes place, among other things, via the intermediates dopaquinone and cysteinyldopa. Cysteine is also necessary if the phaeomelanin is to be created for blonde and reddish hair.
  • Eumelanin is the black-brown pigment. It is mainly about the depth of color of the hair. In brown and black hair it occurs in clearly recognizable granules. Phaeomelanin is the red pigment. It is responsible for light blonde, blonde and red hair. The structure of this melanin is much finer and smaller. The different hair colors result from the different proportions of the melanin types:
  • Blond hair contains little eumelanin and a lot of phaeomelanin.
  • Red hair also has little eumelanin and a lot of phaeomelanin.
  • the pigment formation process can only proceed if sufficient tyrosinase is available. This enzyme is formed less frequently with increasing age. This gradually leads to gray hair. The reason: with little tyrosinase, less and less tyrosine is formed. The production of melanin also decreases. The missing melanin is replaced by the storage of air bubbles. The hair appears gray.
  • This process is usually insidious. It begins at the temples and then extends to the entire hair on the head. Then it hits the beard and eyebrows. Finally, all of the body's hair is gray.
  • gray hair is called canities.
  • canities There are several ways of graying. Premature graying, from the age of 20, is also called Canities praecox.
  • Symptoms of canities, or symptomatic graying of the hair can have various causes. This includes:
  • the cosmetic industry uses lead acetate in some countries, which is toxic and is therefore prohibited in the European Cosmetics Regulation. This lead acetate is preferably applied to the hair as a solution and remains there for a long time without being washed off.
  • keratin fibers e.g. B. hair, wool or furs
  • direct dyes or oxidation dyes which are formed by oxidative coupling of one or more developer components with one another or with one or more coupler components
  • Coupler and developer components are also referred to as oxidation dye precursors.
  • Primary aromatic amines with a further free or substituted hydroxy or amino group located in the para or ortho position, diaminopyridine derivatives, heterocyclic hydrazones, 4-aminopyrazolone derivatives and 2,4,5,6-tetraaminopyrimidine and. are usually used as developer components its derivatives used.
  • Special representatives are, for example, p-phenylenediamine, p-toluenediamine, 2,4,5,6-tetraaminopyrimidine, p-aminophenol, N, N-bis (2-hydroxyethyl) -p-phenylenediamine, 2- (2,5-diaminophenyl ) -ethanol, 2- (2,5-diaminophenoxy) -ethanol, 1-phenyl-3-carboxyamido-4-amino-pyrazolon-5, 4-amino-3-methylphenol, 2-aminomethyl-4-aminophenol, 2- Hydroxy-methyl-4-aminophenol, 2-hydroxy-4,5,6-triaminopyrimidine, 2,4-dihydroxy-5,6-diaminopyrimidine and 2,5,6-triamino-4-hydroxypyrimidine.
  • M-Phenylenediamine derivatives, naphthols, resorcinol and resorcinol derivatives, pyrazolones and m-aminophenols are generally used as coupler components.
  • Particularly suitable coupler substances are ⁇ -naphthol, 1, 5-, 2,7- and 1, 7-dihydroxynaphthalene, 5-amino-2-methylphenol, m-aminophenol, resorcinol, resorcinol monomethyl ether, m-phenylenediamine, 2,4-diaminophenoxyethanol, 1-phenyl-3-methyl-pyrazolon-5, 2,4-di-chloro-3-aminophenol, 1,3-bis (2,4-diaminophenoxy) propane, 2-chlororesorcinol, 4-chlororesorcinol, 2-chloro-6-methyl-3-aminophenol, 2-methylresorcinol and 5-methylresorcinol.
  • oxidation dyes intensive dyeings can be achieved with good fastness properties, but the development of the color is generally done under the influence of oxidizing agents such. B. H 2 O 2 , which in some cases can damage the fiber. Furthermore, some oxidation dye precursors or certain mixtures of oxidation dye precursors can sometimes have a sensitizing effect on people with sensitive skin. Direct dyes are applied under gentler conditions, but their disadvantage is that the dyeings often have inadequate fastness properties.
  • the object of the present invention is to provide colorants for keratin fibers, in particular human hair, which are qualitatively at least equivalent to the usual oxidation hair colorants in terms of color depth, gray coverage and fastness properties, but without necessarily relying on oxidizing agents such as e.g. B. H 2 O 2 to be instructed.
  • the colorants may have no or only a very low sensitization potential.
  • the object of the present invention was therefore to remedy the disadvantages of the prior art.
  • a particular advantage is that the present invention uses physiological processes (increased synthesis of melanin) of the skin and hair in order to obtain the desired pigmentation of the hair and thus the intensification of the hair color.
  • Purines represent a group of important compounds which are widespread in nature and involved in human, animal, plant and microbial metabolic processes, which are derived from the basic body of purine by substitution with OH, NH 2 , SH in 2-, 6- and. Derive 8-position and / or with CH 3 in 1-, 3-, 7-position.
  • the purines are biosynthesized at the nucleotide level from glycine and CO 2 as well as small molecular fragments of L-glutamine, L-aspartic acid and 10- Formyl. Purine bases are released in the metabolism, which are partially recycled in the cells, ie converted into each other.
  • purines include adenine and guanine, which - together with the pyrimidines uracil, thymine and cytosine - are components of the nucleic acids, hypoxanthine, xanthine and uric acid as metabolites of humans and animals as well as the vegetable, often as purine Alkaloids called purines caffeine, theobromine and theophylline, which are found in coffee, cocoa and tea.
  • Plant growth substances to be counted among the purines are zeatin and kinetin (cytokines).
  • cytokines kinetin
  • the innards, especially sweetbreads (thymus) are rich in purines, and fish and green peas also contain a lot.
  • Pyrimidines for the purposes of the present invention are the derivatives of pyrimidine
  • cytosine and thymine are counterpart of adenine and guanine.
  • the role of cytosine in the ribonucleic acid is taken over by uracil.
  • one or more substances selected from the group of pyrimidines and purines increase the activity of the melanocytes in human skin and hair and thus also melanogenesis as a physiological process and thereby increase the natural pigmentation of the hair. This leads to an intensification of the (natural) hair color.
  • Preparations according to the invention advantageously contain 0.0001-20 percent by weight of one or more substances selected from the group of pyrimidines and purines, preferably purine and / or uracil and / or thymine and / or adenine and / or guanine and / or cytosine.
  • Preparations according to the invention preferably contain 0.001-10% by weight of one or more substances, selected from the group of pyrimidines and purines, preferably purine and / or uracil and / or thymine and / or adenine and / or guanine and / or cytosine, based on the total composition of the preparations.
  • Preparations according to the invention very particularly preferably contain 0.01-1% by weight of one or more substances selected from the group of pyrimidines and purines, preferably purine and / or uracil and / or thymine and / or adenine and / or guanine and / or cytosine, based on the total composition of the preparations.
  • the cosmetic and / or dermatological preparations can be composed as usual.
  • the cosmetic and dermatological preparations according to the invention are applied to the scalp and / or the hair in a sufficient amount in the manner customary for cosmetics.
  • the cosmetic and dermatological preparations according to the invention can contain, according to the invention, cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments that have a coloring effect, thickeners, moisturizing and / or moisturizing substances, fats, oils, waxes or other conventional components of a cosmetic or dermatological formulation such as alcohols, polyols, Polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries e.g. Preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments that have a coloring effect, thickeners, moisturizing and / or moisturizing substances, fats, oils, waxes or other conventional components of a cosmetic or dermatological formulation such as alcohols, polyols, Polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • antioxidants are generally preferred. According to the invention, all the antioxidants suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
  • antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Carosin and its derivatives (e.g. anserine), carotenoids, carotenes (e.g. carotene, ß-carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, lipoic acid and their derivatives (e.g.
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • imidazoles eg urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L- Carosin and its derivatives (e.g. anserine)
  • carotenoids e.g. car
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -linoleyl, cholates - ryl and glyceryl esters
  • salts dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfoximines homocysteine sulfoximine, pentahione) Hexa-, heptathioninsulfoximine
  • very low tolerable doses eg pmol to ⁇ mol / kg
  • metal chelators eg ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (eg citric acid, lactic acid, malic acid)
  • Humic acid bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • ⁇ -linolenic acid linoleic acid, oleic acid
  • folic acid and its derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • vitamin E acetate
  • Vitamin A and derivatives vitamin A palmitate
  • the amount of the aforementioned antioxidants (one or more compounds) in the preparations according to the invention is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight of the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to use their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.
  • the lipid phase can advantageously be selected from the following group of substances: mineral oils, mineral waxes
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols with a low C number, for example with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low C number or with fatty acids; benzoates;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions for the purposes of the present invention is advantageously selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms, from the group of esters from aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C- atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethylhexyl ethylhexyl palmitate, ⁇ 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate and synthetic, semi-synthetic and natural mixtures of such esters, for example jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • oil phase is advantageously selected from the group consisting of 2-ethylhexyl isostearate, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 2- i 5 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention.
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and Similar products, furthermore alcohols with a low C number, for example ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides and their derivatives, for example Hyaluronic acid, xanthan rubber, hydroxypropylmethyl cellulose, particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbopols, for example carbopols of types 980, 98
  • the pH is adjusted to 6.
  • the pH is adjusted to 5.5.
  • the pH is adjusted to 3.0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'utilisation d'une ou de plusieurs substances, sélectionnées dans le groupe des pyrimidines et des purines pour renforcer la couleur naturelle des cheveux naturels ou pour stimuler la mélanogenèse des cheveux naturels.
EP02785162A 2001-10-12 2002-10-04 Utilisation d'une ou de plusieurs substances selectionnees dans le groupe des pyrimidines ou des purines dans des preparations cosmetiques de coloration capillaire Withdrawn EP1438005A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10150445 2001-10-12
DE10150445A DE10150445A1 (de) 2001-10-12 2001-10-12 Verwendung einer oder mehreren Substanzen, gewählt aus der Gruppe der Pyrimidine und Purine in kosmetischen Zubereitungen zur Haarfärbung
PCT/EP2002/011158 WO2003032938A1 (fr) 2001-10-12 2002-10-04 Utilisation d'une ou de plusieurs substances selectionnees dans le groupe des pyrimidines ou des purines dans des preparations cosmetiques de coloration capillaire

Publications (1)

Publication Number Publication Date
EP1438005A1 true EP1438005A1 (fr) 2004-07-21

Family

ID=7702313

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02785162A Withdrawn EP1438005A1 (fr) 2001-10-12 2002-10-04 Utilisation d'une ou de plusieurs substances selectionnees dans le groupe des pyrimidines ou des purines dans des preparations cosmetiques de coloration capillaire

Country Status (4)

Country Link
US (1) US20050000040A1 (fr)
EP (1) EP1438005A1 (fr)
DE (1) DE10150445A1 (fr)
WO (1) WO2003032938A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025755A1 (fr) * 2006-09-01 2008-03-06 Basf Se utilisation d'hÉTÉrocycles contenant de l'azote dans les cosmÉtiques dermatologiques
PL2139446T3 (pl) * 2007-04-30 2014-08-29 Unilever Nv Sposób traktowania włosów
EP2005942A1 (fr) * 2007-06-11 2008-12-24 GIULIANI S.p.A. Composition cosmétique pour le traitement de canities
DE102007041493A1 (de) * 2007-08-31 2009-03-05 Henkel Ag & Co. Kgaa Pastellfärbung
DE102009044977A1 (de) * 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Kosmetisches Mittel enthaltend Purin und/oder ein Purinderivat und Sclareol
DE102009044976A1 (de) * 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Verwendung von Purin und/oder einem Purinderivat und mindestens einem Oligonukleotid zur Beeinflussung des natürlichen Pigmentierungsprozesses
US9126056B2 (en) * 2010-04-26 2015-09-08 Energenesis Biomedical Co., Ltd. Method of promoting hair growth
DE102010043069A1 (de) * 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Verwendung von Purin und/oder einem Purinderivat und mindestens einer Aminosäure zur Beeinflussung des natürlichen Pigmentierungsprozesses
DE102010043068A1 (de) * 2010-10-28 2012-05-03 Henkel Ag & Co. Kgaa Verwendung von Purin und/oder einem Purinderivat und mindestens einem Biochinon zur Beeinflussung des natürlichen Pigmentierungsprozesses
ES2784026T3 (es) * 2010-12-15 2020-09-21 Energenesis Biomedical Co Ltd Uso no terapéutico de una composición para promover el crecimiento del cabello
JP6731597B2 (ja) * 2016-04-28 2020-07-29 ホーユー株式会社 色調変化抑制剤及び毛髪化粧料組成物
WO2025080263A1 (fr) * 2023-10-10 2025-04-17 Goren Ofer A Méthodes et compositions pour le traitement de la repigmentation des cheveux

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS533975B2 (fr) * 1973-10-17 1978-02-13 Tokai Electro Chemical Co
FR2654935B1 (fr) * 1989-11-28 1994-07-01 Lvmh Rech Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
US5151425A (en) * 1991-06-20 1992-09-29 Clark Lealand L Method of and composition for treating inflammation and the immunological response thereto
FR2684300B1 (fr) * 1991-11-29 1994-03-11 Lvmh Recherche Composition cosmetique ou pharmaceutique, notamment dermatologique, destinee en particulier a favoriser la pigmentation de la peau ou des cheveux, contenant un extrait de ballote, et son procede de fabrication.
FR2753378B1 (fr) * 1996-09-17 1998-11-20 Oreal Utilisation dans une composition en tant que stimulateur de tyrosinase d'au moins un derive de pyrimidine 3-oxyde, substitue en 6
US5998423A (en) * 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
DE19827624A1 (de) * 1998-06-20 1999-12-23 Beiersdorf Ag Verwendung von einem mit einem Gehalt an Catecinen oder einem Gehalt an Extrakt von grünem Tee in kosmetischen Zubereitungen zur Bräunung der Haut

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03032938A1 *

Also Published As

Publication number Publication date
US20050000040A1 (en) 2005-01-06
DE10150445A1 (de) 2003-04-17
WO2003032938A1 (fr) 2003-04-24

Similar Documents

Publication Publication Date Title
EP1675560A1 (fr) Produits a utiliser sur la peau et/ou les cheveux, contenant des composes cyclohexene 4 fois substitues
EP1776088A1 (fr) Produits pour la peau et/ou les cheveux contenant des composes destines a accentuer le bronzage
WO2005102252A2 (fr) Produits pour la peau et/ou les cheveux, contenant des composes a structure isoprenoide
EP1089707A1 (fr) Utilisation de preparations cosmetiques contenant des catechines ou un extrait de the vert, pour produits bronzants
JP5850266B2 (ja) ヘアケアにおけるステビオール又は誘導体の局所使用
KR102006948B1 (ko) 피부 미백용 화장료 조성물
JP6631805B2 (ja) 白髪化防止のためのヘアケアにおけるエーデルワイス抽出物の使用
WO2005032506A1 (fr) Produits pour la peau et/ou les cheveux contenant des cyclohexenes tetrasubstitues
KR102006952B1 (ko) 주름 예방 및 개선용 화장료 조성물
EP1438005A1 (fr) Utilisation d'une ou de plusieurs substances selectionnees dans le groupe des pyrimidines ou des purines dans des preparations cosmetiques de coloration capillaire
WO2018137854A1 (fr) Associations de principes actifs constituées de trans-4-t-butylcyclohexanol et d'un ou de plusieurs akylamidothiazols et préparations cosmétiques ou dermatologiques contenant ces associations de principes actifs
WO2003003997A2 (fr) Utilisation d'extraits de houblon et/ou de houblon et de malt dans des preparations cosmetiques ou dermatologiques pour prevenir et traiter des symptomes cutanes degeneratifs
WO2002015870A2 (fr) Substances permettant d'induire et d'intensifier les mecanismes de bronzage de la peau et formulations cosmetiques ou dermatologiques contenant ces substances
DE10212865B4 (de) Verwendung von 9-Retinal-alkanolamin Schiffsche Base in kosmetischen der dermatologischen Formulierungen
EP2555745B1 (fr) Utilisation de dihydrodéhydrodiisoeugenol et préparations comprenant du dihydrodéhydrodiisoeugenol
EP1438011A1 (fr) Utilisation d'une ou de plusieurs substances selectionnees dans le groupe des pyrimidines ou des purines dans des preparations cosmetiques pour haler la peau
EP1311233B1 (fr) Substances permettant d'induire et d'intensifier les mecanismes de bronzage de la peau et formulations cosmetiques ou dermatologiques contenant ces substances
DE10221811A1 (de) Malzextrakt enthaltende kosmetischen Zubereitung
WO2002078686A1 (fr) Carbonates de retinyle utilises dans des preparations cosmetiques et dermatologiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GIESEN, KYRA

Inventor name: BLATT, THOMAS

Inventor name: STAEB, FRANZ

Inventor name: SMUDA, CHRISTOPH

Inventor name: WOLBER, RAINER

Inventor name: BERENS, WERNER

17Q First examination report despatched

Effective date: 20050713

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061114